The chief executive and founder of Turing Pharmaceuticals Martin Shkreli has been arrested by the FBI on suspicion of fraud, according to reports.
The 32-year-old sparked outrage in September after he raised the price of Daraprim (pyrimethamine) – used to treat toxoplasmosis, a serious disease that affects AIDS patients and pregnant women and their babies – from $13.50 to $750 a pill.
Turing is one of four companies currently being investigated by the US Senate’s special committee on aging, after dramatically hiking the price of off-patent, life-saving drugs shortly after acquiring them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze